Compare TG Therapeutics Inc (TGTX) vs Western Digital Corp (WDC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TG Therapeutics Inc vs Western Digital Corp — how do they compare? TG Therapeutics Inc trades at $54.77 (market cap $8.36B), while Western Digital Corp trades at $476 (market cap $173.88B). The key difference: Western Digital Corp is far larger — about 20.8× TG Therapeutics Inc's market cap, and Western Digital Corp pays a 0.12% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| TGTX | WDC | |
|---|---|---|
Market Cap | $8.36B | $173.88B |
Sector | Health | Technology |
52-Week High | $59.06 | $746.23 |
52-Week Low | $26.94 | $95.03 |
Enterprise Value | $8.57B | $173.35B |
Dividend Yield | — | 0.12% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TG Therapeutics (TGTX) trades at $55.74, down 0.44% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $64.00. The company reported strong revenue growth, with Q2 2026 revenue reaching $240 million and full-year 2026 guidance raised to approximately $950 million, though recent quarterly EPS results have missed expectations. News highlights include conference participation and institutional buying interest, supporting positive sentiment.
The outlook remains optimistic driven by Briumvi's commercial growth and pipeline catalysts, but risks include earnings volatility, competitive pressures, and reliance on a key product. Upside potential exists if execution meets raised guidance, making it a focus for growth-oriented investors despite near-term profit misses.
Western Digital (WDC) trades at $477.30, up 2.1% on the day, reflecting strong momentum amid bullish technical signals and consistent earnings beats. The stock exhibits robust fundamentals with a net income margin of 71.97% and ROE of 131.02%, supported by positive cash flow trends. Recent news highlights AI-driven storage demand and institutional accumulation, such as CalSTRS increasing its stake by 64,424.3% in Q2 2026 (SEC filing, September 7, 2026).
Outlook remains favorable with a consensus price target of $676.70 (72% buy ratings), though risks include high valuation multiples and cyclical industry exposure. Earnings growth from AI data expansion is a key catalyst, but investor caution is warranted near all-time highs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →About Western Digital Corp
Western Digital is a vertically integrated supplier of data storage solutions, spanning both hard disk drives and solid-state drives. In the HDD market it forms a practical duopoly with Seagate, and it is the largest global producer of NAND flash chips for SSDs in a joint venture with competitor Kioxia.
Read more on WDC →
